Description of a European memory clinic cohort undergoing amyloid‐PET: The AMYPAD Diagnostic and Patient Management Study
Détails
Etat: Public
Version: Final published version
Licence: CC BY-NC 4.0
ID Serval
serval:BIB_31C28BC1BB74
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Description of a European memory clinic cohort undergoing amyloid‐PET: The AMYPAD Diagnostic and Patient Management Study
Périodique
Alzheimer's & Dementia
ISSN
1552-5260
1552-5279
1552-5279
ISSN-L
1552-5260
Statut éditorial
Publié
Date de publication
03/2023
Peer-reviewed
Oui
Volume
19
Numéro
3
Pages
844-856
Langue
anglais
Résumé
AMYPAD Diagnostic and Patient Management Study (DPMS) aims to investigate the clinical utility and cost-effectiveness of amyloid-PET in Europe. Here we present participants' baseline features and discuss the representativeness of the cohort.
Participants with subjective cognitive decline plus (SCD+), mild cognitive impairment (MCI), or dementia were recruited in eight European memory clinics from April 16, 2018, to October 30, 2020, and randomized into three arms: ARM1, early amyloid-PET; ARM2, late amyloid-PET; and ARM3, free-choice.
A total of 840 participants (244 SCD+, 341 MCI, and 255 dementia) were enrolled. Sociodemographic/clinical features did not differ significantly among recruiting memory clinics or with previously reported cohorts. The randomization assigned 35% of participants to ARM1, 32% to ARM2, and 33% to ARM3; cognitive stages were distributed equally across the arms.
The features of AMYPAD-DPMS participants are as expected for a memory clinic population. This ensures the generalizability of future study results.
Participants with subjective cognitive decline plus (SCD+), mild cognitive impairment (MCI), or dementia were recruited in eight European memory clinics from April 16, 2018, to October 30, 2020, and randomized into three arms: ARM1, early amyloid-PET; ARM2, late amyloid-PET; and ARM3, free-choice.
A total of 840 participants (244 SCD+, 341 MCI, and 255 dementia) were enrolled. Sociodemographic/clinical features did not differ significantly among recruiting memory clinics or with previously reported cohorts. The randomization assigned 35% of participants to ARM1, 32% to ARM2, and 33% to ARM3; cognitive stages were distributed equally across the arms.
The features of AMYPAD-DPMS participants are as expected for a memory clinic population. This ensures the generalizability of future study results.
Mots-clé
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Geriatrics and Gerontology, Neurology (clinical), Developmental Neuroscience, Health Policy, Epidemiology
Pubmed
Web of science
Open Access
Oui
Création de la notice
05/07/2022 11:16
Dernière modification de la notice
16/04/2024 7:11
Données d'usage
